Insud Pharma Revenue and Competitors

Madrid, es

Location

N/A

Total Funding

Employee Data

  • Insud Pharma has 6058 Employees.(i)
  • Insud Pharma grew their employee count by 9% last year.

Insud Pharma's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
N/A5522%N/AN/A
#2
N/AN/AN/AN/A
#3
N/A60589%N/AN/A
#4
N/A19524%N/AN/A
#5
N/A15629%N/AN/A
#6
N/A2618%N/AN/A
Add Company

What Is Insud Pharma?

INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health.\n\nWhile the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers` needs in all major pharmaceutical markets. \n\nINSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with more than 9,000 professionals in more than 50 countries, 20 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world.\n\nINSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.

keywords:N/A

N/A

Total Funding

6058

Number of Employees

N/A

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1943.9M66122%N/A
#2
N/A68716%N/A
#3
$2461M77105%N/A
#4
$3277.5M1361125%N/A
#5
$2020.3M144312%N/A